50-Year age threshold for early-onset NSCLC: A SEER-TCGA retrospective analysis reveals a prognostic paradox based on age treatment response.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
410 cases with NSCLC were extracted from the SEER database, 6396 cases were defined as early-onset lung cancer (EOLC), and 155 014 cases as later-onset lung cancer (LOLC).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Molecular analysis revealed five intersecting genes upregulated in EOLC and lower-frequency KRAS/TTN mutations in EOLC tumors. [CONCLUSION] The age threshold for optimal differentiation between patients with EOLC and LOLC is 50 years, Patients with EOLC benefit from aggressive surgery and age-dependent treatment, supported by treatment efficacy and molecular heterogeneity.
[OBJECTIVE] To determine the optimal age threshold for distinguishing early-onset non-small cell lung cancer (NSCLC) and explore the mechanisms underlying its unique prognosis.
- p-value P < 0.001
APA
Lu Z, Zheng P, et al. (2026). 50-Year age threshold for early-onset NSCLC: A SEER-TCGA retrospective analysis reveals a prognostic paradox based on age treatment response.. International journal of surgery (London, England), 112(2), 3989-4011. https://doi.org/10.1097/JS9.0000000000003770
MLA
Lu Z, et al.. "50-Year age threshold for early-onset NSCLC: A SEER-TCGA retrospective analysis reveals a prognostic paradox based on age treatment response.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 3989-4011.
PMID
41342688
Abstract
[OBJECTIVE] To determine the optimal age threshold for distinguishing early-onset non-small cell lung cancer (NSCLC) and explore the mechanisms underlying its unique prognosis.
[METHODS] Cases with NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. X-tile survival analysis and quadratic polynomial fitting identified age thresholds. Random survival forests (RSFs) and restricted cubic splines evaluated age-treatment efficacy interactions. Propensity score matching controlled confounding factors. Molecular analysis used The Cancer Genome Atlas, GEO, cBioPortal database to identify differentially expressed genes and mutations.
[RESULTS] A total of 161 410 cases with NSCLC were extracted from the SEER database, 6396 cases were defined as early-onset lung cancer (EOLC), and 155 014 cases as later-onset lung cancer (LOLC). The optimal cutoff for defining EOLC is 50 years. Patients with EOLC had worse baseline features (EOLC vs. LOLC: 37.3% Stage IV vs. 26.4%, P < 0.001) but superior survival [LOLC: hazard ratio: 1.54, P < 0.001]. Surgery's protective effect declined with age, while chemotherapy and radiotherapy benefits increased. RSF ranked surgery (importance = 0.2584) and age (0.0616) as top prognostic factors. Female and lower lobe tumor location conferred survival advantages. Molecular analysis revealed five intersecting genes upregulated in EOLC and lower-frequency KRAS/TTN mutations in EOLC tumors.
[CONCLUSION] The age threshold for optimal differentiation between patients with EOLC and LOLC is 50 years, Patients with EOLC benefit from aggressive surgery and age-dependent treatment, supported by treatment efficacy and molecular heterogeneity.
[METHODS] Cases with NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. X-tile survival analysis and quadratic polynomial fitting identified age thresholds. Random survival forests (RSFs) and restricted cubic splines evaluated age-treatment efficacy interactions. Propensity score matching controlled confounding factors. Molecular analysis used The Cancer Genome Atlas, GEO, cBioPortal database to identify differentially expressed genes and mutations.
[RESULTS] A total of 161 410 cases with NSCLC were extracted from the SEER database, 6396 cases were defined as early-onset lung cancer (EOLC), and 155 014 cases as later-onset lung cancer (LOLC). The optimal cutoff for defining EOLC is 50 years. Patients with EOLC had worse baseline features (EOLC vs. LOLC: 37.3% Stage IV vs. 26.4%, P < 0.001) but superior survival [LOLC: hazard ratio: 1.54, P < 0.001]. Surgery's protective effect declined with age, while chemotherapy and radiotherapy benefits increased. RSF ranked surgery (importance = 0.2584) and age (0.0616) as top prognostic factors. Female and lower lobe tumor location conferred survival advantages. Molecular analysis revealed five intersecting genes upregulated in EOLC and lower-frequency KRAS/TTN mutations in EOLC tumors.
[CONCLUSION] The age threshold for optimal differentiation between patients with EOLC and LOLC is 50 years, Patients with EOLC benefit from aggressive surgery and age-dependent treatment, supported by treatment efficacy and molecular heterogeneity.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- [Construction of a prognosis forecasting model for breast cancer based on lipid metabolism-related genes and functional verification of ].
- Construction and Validation of Multi-Omics Predictive Models for Colorectal Cancer Using Machine-Learning Approaches.
- Tumor cell AMPK activation enhances NK cell anti-tumor immunity and synergizes with PD-L1 blockade therapy.
- Explainable deep learning for predicting HER-2 expression in breast cancer: a multicenter study.
- AI-driven design of BRAF inhibitors with enhanced binding affinity and optimized drug-likeness.